All scientists must contend with regulation and bureaucracy, despite their frequent complaints that such processes stifle and slow their work. US researchers in gene therapy perhaps feel the pressure of red tape more than most. Is now the right time to ease that burden? The US Institute of Medicine wants to find out. This week, it kicked off a review of an oversight committee that many in gene therapy argue is redundant. They might be right, but when it comes to medical ethics, it is not enough for scientists to do the right thing — they must also be seen to do so.
展开▼
